PARIS , January 19, 2026 : As the medical community gathers for Pharmapack 2026, global med-tech leader BD (Becton, Dickinson and Company) has officially unveiled a suite of innovations aimed at dismantling the final barrier between hospital-grade treatment and home-based care: the delivery of high-viscosity biologics.
Biologics—complex drugs derived from living cells—are the gold standard for treating cancer and autoimmune diseases. However, their molecular structure often makes them as thick as honey (high viscosity). Historically, injecting these fluids required specialized hospital pumps and hours of intravenous (IV) infusion to avoid tissue damage and patient pain.
BD’s new On-Body Injectors (OBIs) represent a paradigm shift in “Patient-Centric” engineering. By utilizing mechanical and digital precision, these devices allow for the safe, subcutaneous (under-the-skin) delivery of large-volume doses that were previously only possible via IV.
The BD Libertas Wearable Injector is designed as a pre-fillable drug delivery system for combination products.
The BD Libertas Wearable Injector is an innovative injection system designed to deliver complex biologics with viscosities up to 50 cP in 2-5 mL and 5-10 mL configurations, at home or in clinical settings.
BD Libertas Wearable Injector features a mechanical spring-based power source, without battery or heavy metals disposal concerns.
BD reinforced its commitment to innovation by completing a 52-subject human clinical trial for its award-winning 2-5 mL BD Libertas Wearable Injector.
The devices are hands-free. Once activated, the injector uses a controlled-release mechanism to deliver the drug over a period of minutes or hours. This allows patients to maintain mobility and go about their daily household activities while receiving life-saving therapy.
BD Libertas Wearable Injector Features
- Single use, fixed dose, prefillable design, with pre-attached adhesive pad
- Dose delivery options: 2-5 mL or 5-10 mL
- Mechanical spring-based power module
- BD glass primary container and needle technology
- Transparent viewing window for drug and drug delivery visibility
- Push button activation
- Color-coded status indicator
BD Libertas Wearable Injector Benefits
- Ready-to-use, simple, design requiring no patient filling or assembly
- Enables hands-free drug delivery
- Designed to conceal the needle before and after injection
- Automated needle insertion and passive needle retraction
- Designed with multiple indications of injection status (audible, tactile, visual) throughout the injection process
- No battery or heavy metals disposal concerns
- Delivered as five component modules in sterile packaging for factory fill/finish and assembly
- Designed for pharma fill/finish utilizing standardized syringe tubs and commercial prefillable syringe filling equipment and processes
- Primary containers available in standard nest and tub configurations
- Stoppers available in TSCF packaging
- No software or electronics supplier management and revision controls required
“As patient expectations continue to evolve and biologics become more complex, drug delivery systems must balance performance, reliability and usability,” said Fernand Goldblat, Vice President and General Manager, BD Medical–Pharmaceutical Systems, Prefillable Syringes Platform. “We look forward to showcasing how BD partners with customers across the development lifecycle to help enable scalable, patient-centric solutions that support both clinical and operational objectives.”
